<!DOCTYPE html><html><head><title>Infection control after hematopoietic cell transplantation (HCT): percentage of patients who were expected to be neutropenic for 7 or more days during HCT and were prescribed antibacterial prophylaxis with a fluoroquinolone.</title><link rel="stylesheet" type="text/css" href="style.css"></head><body><div class='section'>
<h2>General
</h2>
<div class='field field_text'>
<h3>
Title
</h3>
<div class='FieldValue'>
<div class="content_title">Infection control after hematopoietic cell transplantation (HCT): percentage of patients who were expected to be neutropenic for 7 or more days during HCT and were prescribed antibacterial prophylaxis with a fluoroquinolone.</div>
</div>

</div>
<div class='field field_citation'>
<h3>
Source(s)
</h3>
<div class='FieldValue'>
<table><tr><td>Proposed infection control after HCT measure set: questionnaire, patient selection, measures with specifications, glossary. Arlington Heights (IL): American Society for Blood and Marrow Transplantation; 20 p. </td></tr></table>
</div>

</div>

</div>
<div class='section'>
<h2>Measure Domain
</h2>
<div class='field field_picklist-one'>
<h3>
Primary Measure Domain
</h3>
<div class='FieldValue'>
Clinical Quality Measures: Process
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Secondary Measure Domain
</h3>
<div class='FieldValue'>
Does not apply to this measure
</div>

</div>

</div>
<div class='section'>
<h2>Brief Abstract
</h2>
<div class='field field_text'>
<h3>
Description
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This measure is used to assess the percentage of patients greater than or equal to 18 years of age who were expected to be neutropenic for 7 or more days during hematopoietic cell transplantation (HCT) and were prescribed antibacterial prophylaxis with a fluoroquinolone.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Rationale
</h3>
<div class='FieldValue'>
<div class="content_para"><p>In the past decade, modifications in hematopoietic cell transplantation (HCT) management and supportive care have resulted in changes in recommendations for the prevention of infection in HCT patients. These changes are fueled by new antimicrobial agents, increased knowledge of immune reconstitution, and expanded conditioning regimens and patient populations eligible for HCT. Despite these advances, infection is reported as the primary cause of death in 8% of autologous HCT patients and 17% to 20% of allogeneic HCT recipients. </p>
<p><em>Support (verbatim) from guidelines</em>: Antibacterial prophylaxis with a fluoroquinolone (i.e., levofloxacin) to prevent bacterial infections should be strongly considered for adult HCT patients with anticipated neutropenic periods of 7 days or more. Antibacterial prophylaxis is generally started at the time of stem cell infusion and continued until recovery from neutropenia or initiation of empirical antibacterial therapy for fever during neutropenia. The prophylaxis should not be continued after recovery from neutropenia. Local epidemiological data should be carefully considered before applying fluoroquinolone prophylaxis, and once it is applied, the emergence of resistance in bacterial pathogens should be monitored closely because of increasing quinolone resistance worldwide among Gram-negative bacteria (e.g., <em>Escherichia coli</em>, <em>Klebsiella pneumoniae</em>, and <em>Pseudomonas aeruginosa</em>) and staphylococci; plasmid-mediated quinolone resistance in Enterobacteriaceae that is closely related to the beta lactamases that inactivate third-generation cephalosporins; and quinolone-related development of a hypervirulent strain of <em>Clostridium difficile</em>. </p>
<p><em>Note on pediatrics</em>: Because of lack of data, there are currently no antimicrobial prophylactic regimens that can be recommended for children. Some experts use levofloxacin for pediatric antibacterial prophylaxis. </p>
<p><em>Statement (verbatim) from guidelines on gap</em>: Significant changes in the field of HCT since the publication of the original guidelines necessitated this update. These changes include new antimicrobial agents, broader use of reduced-intensity conditioning (RIC), the increasing age of HCT recipients, and more frequent use of alternative donor stem cell sources such as haploidentical donors and umbilical cord blood. Furthermore, as with any field of medicine, published studies continue to add to the evidence regarding supportive medical care. Despite&mdash;or perhaps because of&mdash;these changes, infections still occur with increased frequency or severity among HCT recipients as a patient population.</p>
<p><em>Statement from the American Society for Blood and Marrow Transplantation (ASBMT) Task Force on gap</em>: Fluoroquinolone for bacterial infection prophylaxis is new to the 2009 guidelines from the prior 2000 guidelines. For this reason, we believe there is a significant gap in adoption of this therapy. </p></div>
</div>

</div>
<div class='field field_citation'>
<h3>
Evidence for Rationale
</h3>
<div class='FieldValue'>
<table><tr><td>&nbsp;Pasquini MC, Wang Z. &nbsp;Current use and outcome of hematopoietic stem cell transplantation: CIBMTR summary slides. &nbsp;2012. </td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Blahova J, Kralikova K, Krcmery V Sr, Babalova M, Menkyna R, Glosova L, Knotkova H, Liskova A, Molokacova M, Vaculikova A, Bruckmayerova D, Rovny I. Four years of monitoring antibiotic resistance in microorganisms from bacteremic  patients. J Chemother. 2007 Dec;19(6):665-9. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=18230547" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Bonadio M, Morelli G, Mori S, Riccioni R, Papineschi F, Petrini M. Fluoroquinolone resistance in hematopoietic stem cell transplant recipients with  infectious complications. Biomed Pharmacother. 2005 Oct;59(9):511-6. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16274955" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Bucaneve G, Castagnola E, Viscoli C, Leibovici L, Menichetti F. Quinolone prophylaxis for bacterial infections in afebrile high risk neutropenic patients. Eur J Cancer. 2007;(Suppl 5):5-12.</td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Bucaneve G, Micozzi A, Menichetti F, Martino P, Dionisi MS, Martinelli G, Allione B, D'Antonio D, Buelli M, Nosari AM, Cilloni D, Zuffa E, Cantaffa R, Specchia G, Amadori S, Fabbiano F, Deliliers GL, Lauria F, Foa R, Del Favero A, Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) Infection Program. Levofloxacin to prevent bacterial infection in patients with cancer and neutropenia. N Engl J Med. 2005 Sep 8;353(10):977-87. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16148283" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Cruciani M, Malena M, Bosco O, Nardi S, Serpelloni G, Mengoli C. Reappraisal with meta-analysis of the addition of Gram-positive prophylaxis to fluoroquinolone in neutropenic patients. J Clin Oncol. 2003 Nov 15;21(22):4127-37. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=14615441" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Cruciani M, Rampazzo R, Malena M, Lazzarini L, Todeschini G, Messori A, Concia E. Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis. 1996 Oct;23(4):795-805. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=8909847" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Engels EA, Lau J, Barza M. Efficacy of quinolone prophylaxis in neutropenic cancer patients: a meta-analysis. J Clin Oncol. 1998 Mar;16(3):1179-87. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=9508206" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Gafter-Gvili A, Fraser A, Paul M, Leibovici L. Meta-analysis: antibiotic prophylaxis reduces mortality in neutropenic patients. Ann Intern Med. 2005 Jun 21;142(12 Pt 1):979-95. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15968013" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Kirby JT, Fritsche TR, Jones RN. Influence of patient age on the frequency of occurrence and antimicrobial resistance patterns of isolates from hematology/oncology patients. Diagn Microbiol Infect Dis. 2006 Sep;56(1):75-82. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16876375" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Loo VG, Poirier L, Miller MA, Oughton M, Libman MD, Michaud S, Bourgault AM, Nguyen T, Frenette C, Kelly M, Vibien A, Brassard P, Fenn S, Dewar K, Hudson TJ, Horn R, Rene P, Monczak Y, Dascal A. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med. 2005 Dec 8;353(23):2442-9. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16322602" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>MacDougall C, Powell JP, Johnson CK, Edmond MB, Polk RE. Hospital and community fluoroquinolone use and resistance in Staphylococcus aureus and Escherichia coli in 17 US hospitals. Clin Infect Dis. 2005 Aug 15;41(4):435-40. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=16028149" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Oktem IM, Gulay Z, Bicmen M, Gur D, HITIT Project Study Group. qnrA prevalence in extended-spectrum beta-lactamase-positive Enterobacteriaceae isolates from Turkey. Jpn J Infect Dis. 2008 Jan;61(1):13-7. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=18219128" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Poirel L, Cattoir V, Nordmann P. Is plasmid-mediated quinolone resistance a clinically significant problem. Clin Microbiol Infect. 2008 Apr;14(4):295-7. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=18190576" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Proposed infection control after HCT measure set: questionnaire, patient selection, measures with specifications, glossary. Arlington Heights (IL): American Society for Blood and Marrow Transplantation; 20 p. </td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Robicsek A, Jacoby GA, Hooper DC. The worldwide emergence of plasmid-mediated quinolone resistance. Lancet Infect Dis. 2006 Oct;6(10):629-40. [77 references] <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=17008172" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>The European Antimicrobial Resistance Surveillance System (EARSS). Annual report 2006. 2008. </td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>Tomblyn M, Chiller T, Einsele H, Gress R, Sepkowitz K, Storek J, Wingard JR, Young JA, Boeckh MJ, Center for International Blood and Marrow Research, National Marrow Donor program, European Blood and Marrow Transplant Group, American Society of Blood and Marrow Transplantation, Canadian Blood and Marrow Transplant Group, Infectious Diseases Society of America, Society for Healthcare Epidemiology of America, Association of Medical Microbiology and Infectious Disease Canada, Centers for Disease Control and Prevention. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective. Biol Blood Marrow Transplant. 2009 Oct;15(10):1143-238. <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=19747629" target="_blank">PubMed</a></td></tr></table>
</div>
<div class='FieldValue'>
<table><tr><td>van de Wetering MD, de Witte MA, Kremer LC, Offringa M, Scholten RJ, Caron HN. Efficacy of oral prophylactic antibiotics in neutropenic afebrile oncology patients: a systematic review of randomised controlled trials. Eur J Cancer. 2005 Jul;41(10):1372-82. [44 references] <a href="http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract&list_uids=15913983" target="_blank">PubMed</a></td></tr></table>
</div>

</div>
<div class='field field_text'>
<h3>
Primary Health Components
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Hematopoietic cell transplantation (HCT); neutropenia; antibacterial prophylaxis; fluoroquinolone</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Denominator Description
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The number of patients in your selection having hematopoietic cell transplantation (HCT) AND expected to be neutropenic for 7 or more days (see the related "Denominator Inclusions/Exclusions" field)</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Numerator Description
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The number of patients in your selection having hematopoietic cell transplantation (HCT) AND expected to be neutropenic for 7 or more days AND were prescribed fluoroquinolone (see the related "Numerator Inclusions/Exclusions" field)</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Evidence Supporting the Measure
</h2>
<div class='field field_picklist-choice'>
<h3>
Type of Evidence Supporting the Criterion of Quality for the Measure
</h3>
<div class='FieldValue'>
A clinical practice guideline or other peer-reviewed synthesis of the clinical research evidence
</div>
<div class='FieldValue'>
A formal consensus procedure, involving experts in relevant clinical, methodological,  public health and organizational sciences
</div>
<div class='FieldValue'>
A systematic review of the clinical research literature (e.g., Cochrane Review)
</div>
<div class='FieldValue'>
One or more research studies published in a National Library of Medicine (NLM) indexed, peer-reviewed journal
</div>

</div>
<div class='field field_text'>
<h3>
Additional Information Supporting Need for the Measure
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Extent of Measure Testing
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The Infection Control (IC) measure set was developed by the American Society for Blood and Marrow Transplantation (ASBMT) using a rigorous methodology (adapted from the American Medical Association's Physician Consortium for Performance Improvement [AMA-PCPI] and including field testing) and adapted for use in Practice Improvement Modules (PIMs) by the American Board of Internal Medicine (ABIM).</p></div>
</div>

</div>
<div class='field field_citation'>
<h3>
Evidence for Extent of Measure Testing
</h3>
<div class='FieldValue'>
<table><tr><td>Joseph TL. (Executive Director, American Society for Blood and Marrow Transplantation). Personal communication. 2013 Jan 21. &nbsp;1 p. </td></tr></table>
</div>

</div>

</div>
<div class='section'>
<h2>State of Use of the Measure
</h2>
<div class='field field_picklist-one'>
<h3>
State of Use
</h3>
<div class='FieldValue'>
Current routine use
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Current Use
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>

</div>
<div class='section'>
<h2>Application of the Measure in its Current Use
</h2>
<div class='field field_picklist-choice'>
<h3>
Measurement Setting
</h3>
<div class='FieldValue'>
Ambulatory/Office-based Care
</div>
<div class='FieldValue'>
Hospital Inpatient
</div>
<div class='FieldValue'>
Hospital Outpatient
</div>
<div class='FieldValue'>
Intensive Care Units
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Professionals Involved in Delivery of Health Services
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Least Aggregated Level of Services Delivery Addressed
</h3>
<div class='FieldValue'>
Clinical Practice or Public Health Sites
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Statement of Acceptable Minimum Sample Size
</h3>
<div class='FieldValue'>
Specified
</div>

</div>
<div class='field field_text'>
<h3>
Target Population Age
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Age greater than or equal to&nbsp;18 years </p></div>
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Target Population Gender
</h3>
<div class='FieldValue'>
Either male or female
</div>

</div>

</div>
<div class='section'>
<h2>National Strategy for Quality Improvement in Health Care
</h2>
<div class='field field_text'>
<h3>
National Quality Strategy Aim
</h3>
<div class='FieldValue'>
<ul><li>Better Care</li></ul>
</div>

</div>
<div class='field field_text'>
<h3>
National Quality Strategy Priority
</h3>
<div class='FieldValue'>
<ul><li>Making Care Safer</li><li>Prevention and Treatment of Leading Causes of Mortality</li></ul>
</div>

</div>

</div>
<div class='section'>
<h2>Institute of Medicine (IOM) National Health Care Quality Report Categories
</h2>
<div class='field field_picklist-choice'>
<h3>
IOM Care Need
</h3>
<div class='FieldValue'>
Living with Illness
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
IOM Domain
</h3>
<div class='FieldValue'>
Effectiveness
</div>
<div class='FieldValue'>
Safety
</div>

</div>

</div>
<div class='section'>
<h2>Data Collection for the Measure
</h2>
<div class='field field_text'>
<h3>
Case Finding Period
</h3>
<div class='FieldValue'>
<div class="content_para"><p>12 months</p></div>
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Denominator Sampling Frame
</h3>
<div class='FieldValue'>
Patients associated with provider
</div>

</div>
<div class='field field_picklist-choice'>
<h3>
Denominator (Index) Event or Characteristic
</h3>
<div class='FieldValue'>
Clinical Condition
</div>
<div class='FieldValue'>
Encounter
</div>
<div class='FieldValue'>
Therapeutic Intervention
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Denominator Time Window
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>
<div class='field field_text'>
<h3>
Denominator Inclusions/Exclusions
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong>Inclusions </strong><br />
The number of patients in your selection having hematopoietic cell transplantation (HCT) AND expected to be neutropenic for 7 or more days</p>
<p class="Note"><strong>Note</strong>: Patients can be included in the chart abstraction if: </p>
<ul class="Note" style="list-style-type: disc;">
    <li>They have been seen by the practice within the past 12 months; and </li>
    <li>Management decisions regarding care are made primarily by providers in the practice. </li>
</ul>
<p class="Note">Select at least 25 of your patients who have had HCT. Refer to the original measure documentation for administrative codes.</p>
<p><strong>Exclusions</strong> <br />
Patients less than 18 years old </p></div>
</div>

</div>
<div class='field field_picklist-choice-4'>
<h3>
Exclusions/Exceptions
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>
<div class='field field_text'>
<h3>
Numerator Inclusions/Exclusions
</h3>
<div class='FieldValue'>
<div class="content_para"><p><strong>Inclusions</strong><br />
The number of patients in your selection having hematopoietic cell transplantation (HCT) AND expected to be neutropenic for 7 or more days AND were prescribed fluoroquinolone </p>
<p class="Note"><strong>Note</strong>: This requires documentation in the patient's medical record that fluoroquinolone therapy was prescribed as described in the guidelines (see the original measure documentation for details).</p>
<p><strong>Exclusions</strong><br />
None</p></div>
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Numerator Search Strategy
</h3>
<div class='FieldValue'>
Fixed time period or point in time
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Data Source
</h3>
<div class='FieldValue'>
Administrative clinical data
</div>
<div class='FieldValue'>
Paper medical record
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Type of Health State
</h3>
<div class='FieldValue'>
Does not apply to this measure
</div>

</div>
<div class='field field_text'>
<h3>
Instruments Used and/or Associated with the Measure
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Computation of the Measure
</h2>
<div class='field field_picklist-one'>
<h3>
Measure Specifies Disaggregation
</h3>
<div class='FieldValue'>
Does not apply to this measure
</div>

</div>
<div class='field field_picklist-many'>
<h3>
Scoring
</h3>
<div class='FieldValue'>
Rate/Proportion
</div>

</div>
<div class='field field_picklist-one'>
<h3>
Interpretation of Score
</h3>
<div class='FieldValue'>
Desired value is a higher score
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Allowance for Patient or Population Factors
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>
<div class='field field_picklist-choice-3'>
<h3>
Standard of Comparison
</h3>
<div class='FieldValue'>
not defined yet
</div>

</div>

</div>
<div class='section'>
<h2>Identifying Information
</h2>
<div class='field field_text'>
<h3>
Original Title
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Patients who were expected to be neutropenic for 7 or more days during HCT and were prescribed antibacterial prophylaxis with a fluoroquinolone.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Measure Collection Name
</h3>
<div class='FieldValue'>
Infection Control after Hematopoietic Cell Transplantation Measure Set
</div>

</div>
<div class='field field_orglist'>
<h3>
Submitter
</h3>
<div class='FieldValue'>
American Society for Blood and Marrow Transplantation - Professional Association
</div>

</div>
<div class='field field_orglist-p'>
<h3>
Developer
</h3>
<div class='FieldValue'>
American Society for Blood and Marrow Transplantation - Professional Association
</div>

</div>
<div class='field field_text'>
<h3>
Funding Source(s)
</h3>
<div class='FieldValue'>
<div class="content_para"><p>American Society for Blood and Marrow Transplantation</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Composition of the Group that Developed the Measure
</h3>
<div class='FieldValue'>
<div class="content_para"><p>The American Society for Blood and Marrow Transplantation (ASBMT) Education Practice Improvement Modules Task Force:</p>
<ul style="list-style-type: disc;">
    <li>Linda Burns, MD (<em>chair</em>) </li>
    <li>Stephan A Grupp, MD, PhD </li>
    <li>Mark B Juckett, MD </li>
    <li>Vivek Roy, MD </li>
    <li>Edward Agura, MD </li>
    <li>Miguel-Angel Perales, MD </li>
    <li>Thomas Joseph, MPS, CAE, ASBMT Executive Director </li>
    <li>Sue Frechette, BSN, MBA Consultant </li>
</ul></div>
</div>

</div>
<div class='field field_text'>
<h3>
Financial Disclosures/Other Potential Conflicts of Interest
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Conflicts, if any, are disclosed in accordance with the American Society for Blood and Marrow Transplantation (ASBMT) conflict of interest policy.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Adaptation
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This measure was not adapted from another source.</p></div>
</div>

</div>
<div class='field field_date'>
<h3>
Date of Most Current Version in NQMC
</h3>
<div class='FieldValue'>
2012 Apr
</div>

</div>
<div class='field field_text'>
<h3>
Measure Maintenance
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Date of Next Anticipated Revision
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Unspecified</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Measure Status
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This is the current release of the measure.</p>
<p>The measure developer reaffirmed the currency of this measure in February 2017. </p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Measure Availability
</h3>
<div class='FieldValue'>
<div class="content_para"><p>Source not available electronically.</p>
<p>For more information, contact the American Society for Blood and Marrow Transplantation (ASBMT) at 85 W. Algonquin Road, Suite 550, Arlington Heights, IL 60005; Phone: 847-427-0224; Fax: 847-427-9656; Web site: <a href="http://www.asbmt.org" title="ASBMT Web site">www.asbmt.org</a>; E-mail: <a href="mailto:mail@asbmt.org">mail@asbmt.org</a>.</p></div>
</div>

</div>
<div class='field field_text'>
<h3>
NQMC Status
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This NQMC summary was completed by ECRI Institute on September 24, 2013. The information was verified by the measure developer on October 25, 2013.</p>
<p>The information was reaffirmed by the measure developer on February 8, 2017. </p></div>
</div>

</div>
<div class='field field_text'>
<h3>
Copyright Statement
</h3>
<div class='FieldValue'>
<div class="content_para"><p>This NQMC summary is based on the original measure, which is subject to the measure developer's copyright restrictions.</p></div>
</div>

</div>

</div>
<div class='section'>
<h2>Production
</h2>
<div class='field field_citation'>
<h3>
Source(s)
</h3>
<div class='FieldValue'>
<table><tr><td>Proposed infection control after HCT measure set: questionnaire, patient selection, measures with specifications, glossary. Arlington Heights (IL): American Society for Blood and Marrow Transplantation; 20 p. </td></tr></table>
</div>

</div>

</div>
<div class='section'>
<h2>Disclaimer
</h2>
<div class='field field_text'>
<h3>
NQMC Disclaimer
</h3>
<div class='FieldValue'>
<p>The National Quality Measures Clearinghouse™ (NQMC) does not develop, produce, approve, or endorse the measures represented on this site.</p> 
<p>All measures summarized by NQMC and hosted on our site are produced under the auspices of medical specialty societies, relevant professional associations, public and private organizations, other government agencies, health care organizations or plans, individuals, and similar entities.</p> 
<p>Measures represented on the NQMC Web site are submitted by measure developers, and are screened solely to determine that they meet the <a href="/help-and-about/summaries/inclusion-criteria">NQMC Inclusion Criteria</a>.</p> 
<p>NQMC, AHRQ, and its contractor ECRI Institute make no warranties concerning the content or its reliability and/or validity of the quality measures and related materials represented on this site. Moreover, the views and opinions of developers or authors of measures represented on this site do not necessarily state or reflect those of NQMC, AHRQ, or its contractor, ECRI Institute, and inclusion or hosting of measures in NQMC may not be used for advertising or commercial endorsement purposes.</p> 
<p>Readers with questions regarding measure content are directed to contact the measure developer.</p>
</div>

</div>

</div>
</body></html>